Cambridge (UK) – Muscarinic receptor agonists like pilocarpine demonstrably boost amounts of secreted saliva, and are therefore promising agents for the treatment of xerostomia (dry mouth), a common discomfort following cancer therapy of patients with head and neck cancer. In July, British Acacia Pharma Ltd initiated a Phase II efficacy study in advanced cancer patients of APD515, an new oromucosal formulation of a marketed muscarinic receptor agonist. In the course of the trial, the 30 patients will either receive a placebo or a daily oromucosal 15mg administration of APD515 over 7 days, followed by a washout week, and then the reverse of what they received in week one during the third week. Patients will grade their symptoms before and after treatment, and their salivary flow will be measured. Acacia expects results of the trial in Q4/2011.